Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Investment analysts at HC Wainwright issued their Q4 2027 earnings per share (EPS) estimates for shares of Candel Therapeutics in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per share of ($0.34) for the quarter. HC Wainwright currently has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.29) per share.
Several other brokerages also recently weighed in on CADL. UBS Group restated a "buy" rating on shares of Candel Therapeutics in a research note on Monday, August 17th. Jefferies Financial Group assumed coverage on shares of Candel Therapeutics in a report on Thursday, October 22nd. They set a "buy" rating and a $25.00 price target for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Candel Therapeutics in a research note on Thursday, October 15th. Bank of America upgraded shares of Candel Therapeutics from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $12.00 to $18.00 in a report on Monday, September 21st. Finally, Canaccord Genuity Group decreased their price objective on shares of Candel Therapeutics from $25.00 to $13.00 and set a "buy" rating for the company in a research report on Friday. Nine investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.57.
Read Our Latest Stock Report on Candel Therapeutics
Candel Therapeutics Price Performance
Shares of NASDAQ:CADL opened at $6.20 on Monday. The company has a market capitalization of $474.42 million, a price-to-earnings ratio of -4.19 and a beta of -0.27. The company has a 50 day moving average of $9.75 and a two-hundred day moving average of $8.39. Candel Therapeutics has a 52-week low of $4.35 and a 52-week high of $14.00. The company has a quick ratio of 7.57, a current ratio of 7.57 and a debt-to-equity ratio of 0.37.
Candel Therapeutics (NASDAQ:CADL - Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.34) by $0.06.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the stock. Entropy Technologies LP bought a new stake in shares of Candel Therapeutics in the 3rd quarter worth about $266,000. Jump Financial LLC lifted its position in shares of Candel Therapeutics by 22.2% during the third quarter. Jump Financial LLC now owns 130,579 shares of the company's stock worth $1,363,000 after purchasing an additional 23,739 shares during the last quarter. ACT Capital Partners L.P. bought a new position in shares of Candel Therapeutics during the third quarter worth about $1,571,000. Russell Investments Group Ltd. lifted its position in shares of Candel Therapeutics by 172.6% during the third quarter. Russell Investments Group Ltd. now owns 43,639 shares of the company's stock worth $456,000 after purchasing an additional 27,632 shares during the last quarter. Finally, AlphaCentric Advisors LLC lifted its position in shares of Candel Therapeutics by 4.3% during the third quarter. AlphaCentric Advisors LLC now owns 38,259 shares of the company's stock worth $399,000 after purchasing an additional 1,576 shares during the last quarter. 13.93% of the stock is currently owned by institutional investors.
Key Stories Impacting Candel Therapeutics
Here are a few of the latest stories about CADL:
- Positive Sentiment: Candel reported a third-quarter loss of $0.28 per share, narrower than analysts’ expected loss of $0.34. Third-quarter results and corporate update
- Negative Sentiment: The company now expects to submit its biologics license application for aglatimagene in mid-2027. The delay followed FDA discussions and pushed back a key potential catalyst, prompting sharp selling. Mid-2027 BLA plan
- Negative Sentiment: Reports also cited a wider operating loss, adding to concerns as investors reassess the company’s timeline and financial outlook. Operating loss and FDA discussion
About Candel Therapeutics
(
Get Free Report)
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company's clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Candel Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.
While Candel Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.